Simeprevir Has High SVR Rate in Hep C Trial
The Editors at Hepatitis Central
May 28, 2013
Print this page
In a Phase III Hepatitis C trial of triple therapy with pegylated interferon and ribavirin, simeprevir proves itself by leading to sustained virologic response in nearly 80 percent of patients.
Sustained Virologic Response with Simeprevir for Hepatitis C
May 21, 2013
Janssen R&D Ireland announced primary efficacy and safety results from its global Phase 3 PROMISE study. Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.
Continue reading this entire article:
HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.